The Ultimate Guide To Imipenem
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To judge a number of intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Major demo objectives were being to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polym